Stocks Health care APUS
NYSE · Health careApimeds Pharmaceuticals US, Inc. (APUS)
It posted a net loss of $58.2M. In fiscal 2025 capital spending exceeded operating cash flow by $9M. At June 30, 2026 it held $278.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Apimeds Pharmaceuticals US, Inc.
- Net worth
- Apimeds Pharmaceuticals US, Inc. has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $106.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $8.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Apimeds Pharmaceuticals US, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Apimeds Pharmaceuticals US, Inc. does
Apimeds Pharmaceuticals US, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker APUS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$6M | -$0.55 | -$9M |
| 2024 | n/a | -$1.4M | -$0.18 | n/a |
| 2024 | n/a | -$777.7K | -$0.17 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Apimeds Pharmaceuticals US, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Executive or director change8-KApimeds Pharmaceuticals appointed Eric Sherb as Chief Financial Officer following the resignation of Interim CFO Erick Frim.
- September 29, 2026Other event 8-K
- September 23, 2026
- September 11, 2026
- August 21, 2026
- August 14, 2026
- August 6, 2026Other event 8-K
- July 13, 2026Other event 8-K
- May 26, 2026
- May 15, 2026Late quarterly report notice NT 10-Q
Insider trades
What the people running Apimeds Pharmaceuticals US, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns APUS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Apimeds Inc.13D, may seek influence with 1 related filers | 34.3% | May 7, 2026 |
| Ayrton Capital LLC13G, passive with 2 related filers | 9.99% | February 11, 2026 |
Largest institutional holders
Insiders
Questions about APUS
What does Apimeds Pharmaceuticals US, Inc. do?
Apimeds Pharmaceuticals US, Inc. is a company in the Health care sector, listed on NYSE as APUS. Its shares trade on NYSE under the ticker APUS.
What is Apimeds Pharmaceuticals US, Inc.'s net worth?
Apimeds Pharmaceuticals US, Inc. has a market value (market cap) of $4.1M at the latest share price, and shareholders' equity of $106.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Apimeds Pharmaceuticals US, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $58.2M.
When did Apimeds Pharmaceuticals US, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 1, 2026.
When is Apimeds Pharmaceuticals US, Inc.'s next earnings report?
Apimeds Pharmaceuticals US, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare APUS with
Follow APUS
Get an email when Apimeds Pharmaceuticals US, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Apimeds Pharmaceuticals US, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.